Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No.  2003D-0466]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA) is announcing the availability of a guidance document for industry (#160) entitled “Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food:  Repeat-Dose (Chronic) Toxicity Testing” (VICH GL-37). This guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH).  This VICH guidance document is intended to establish recommendations for internationally harmonized repeat-dose chronic toxicity testing.

# DATES:

Submit written or electronic comments at any time.

# ADDRESSES:

                        Submit written requests for single copies of the guidance to the Communications Staff (HFV-12), Center for Veterinary Medicine (CVM), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855.  Send one self-addressed adhesive label to assist that office in processing your requests.  See the                         **SUPPLEMENTARY INFORMATION**                         section for electronic access to the guidance document.                    

                        Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.  Submit electronic comments to                         *http://www.fda.gov/​dockets/​ecomments*. Comments should be identified with the full title of the guidance and the docket number found in brackets in the heading of this document.                    

# FOR FURTHER INFORMATION CONTACT:

                        Louis T. Mulligan, Center for Veterinary Medicine (HFV-153), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6984, e-mail:                         *lmulliga@cvm.fda.gov*.                    

# SUPPLEMENTARY INFORMATION:

## I.  Background

                    In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote the international harmonization of regulatory requirements.  FDA has participated in efforts to enhance harmonization and has expressed its commitment to seek scientifically based harmonized technical procedures for the development of pharmaceutical products.  One of the goals of harmonization is to identify and then reduce differences in technical requirements for drug development                           ( print page 6450)                        among regulatory agencies in different countries.                

FDA has actively participated in the International Conference on Harmonisation of Technical Requirements for Approval of Pharmaceuticals for Human Use for several years to develop harmonized technical requirements for the approval of human pharmaceutical and biological products among the European Union, Japan, and the United States.  The VICH is a parallel initiative for veterinary medicinal products.  The VICH is concerned with developing harmonized technical requirements for the approval of veterinary medicinal products in the European Union, Japan, and the United States, and includes input from both regulatory and industry representatives.

The VICH Steering Committee is composed of member representatives from the European Commission, European Medicines Evaluation Agency; European Federation of Animal Health; Committee on Veterinary Medicinal Products; the U.S. FDA; the U.S. Department of Agriculture; the Animal Health Institute; the Japanese Veterinary Pharmaceutical Association; the Japanese Association of Veterinary Biologics; and the Japanese Ministry of Agriculture, Forestry and Fisheries.

Four observers are eligible to participate in the VICH Steering Committee:  One representative from the government of Australia/New Zealand, one representative from the industry in Australia/New Zealand, one representative from the government of Canada, and one representative from the industry of Canada.  The VICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation for Animal Health (IFAH).  An IFAH representative also participates in the VICH Steering Committee meetings.

## II.  Guidance on Repeat-Dose Chronic Toxicity Testing

                    In the                     **Federal Register**                     of October 23, 2003 (68 FR 60703), FDA published the notice of availability of the VICH draft guidance, giving interested persons until November 24, 2003, to submit comments.  After consideration of comments received, the draft guidance was changed in response to the comments and submitted to the VICH Steering Committee.  At a meeting held on May 3, 2004, the VICH Steering Committee endorsed the final guidance for industry, VICH GL-37.    This VICH guidance is one of a series of guidances developed to facilitate the mutual acceptance of safety data necessary for the determination of acceptable daily intakes for veterinary drug residues in human food.  This guidance was developed after consideration of the current practices for evaluating veterinary drug residues in human food in the European Union, Japan, the United States, Australia, New Zealand, and Canada.  It also took account of available data from subchronic and chronic toxicity studies.                

Information collection is covered under the Office of Management and Budget (OMB) control number 0910-0032.

## III. Significance of Guidance

This document, developed under the VICH process, has been revised to conform to FDA's good guidance practices regulation (21 CFR 10.115).  For example, the document has been designated “guidance” rather than “guideline.”  Because guidance documents are not binding, mandatory words such as “must,” “shall,” and “will” in the original VICH document have been substituted with “should.” Similarly, words such as “require” or “requirement” have been replaced by “recommend” or “recommendation” as appropriate to the context.

The VICH guidance (#160) is consistent with the agency's current thinking on the safety of residues of veterinary drugs in human foods.  This guidance does not create or confer any rights for or on any person and will not operate to bind FDA or the public.  An alternative method may be used as long as it satisfies the requirements of applicable statutes and regulations.

## IV. Comments

                    As with all of FDA's guidances, the public is encouraged to submit written or electronic comments pertinent to this guidance. FDA will periodically review the comments in the docket and, where appropriate, will amend the guidance. The agency will notify the public of any such amendments through a notice in the                     **Federal Register**                    .                

                    Interested persons may submit to the Division of Dockets Management (see                     **ADDRESSES**                    ) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.                

## V.  Electronic Access

                    Copies of the guidance document entitled “Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food:  Repeat-Dose (Chronic) Toxicity Testing” (VICH GL-37) may be obtained on the Internet from the CVM home page at                     *http://www.fda.gov/​cvm*.                

Dated:  January 25, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 05-2266 Filed 2-4-05; 8:45 am]

BILLING CODE 4160-01-S